IceCure Medical Ltd. filed its nine-month financial and operating results for the period ended September 30, 2026, reporting on November 18, 2026, with total revenues rising approximately 26% year over year and an expanded U.S. commercial footprint.
Key Highlights
- 26% revenue increase: Total revenues for the nine months ended September 30, 2026 rose to approximately $2.6 million, compared to $2.1 million in the same period of 2025.
- 83% U.S. sales growth: U.S. sales of ProSense and its cryoprobes doubled year over year during the first nine months of 2026 compared to the same period in 2025, according to the filing.
- Expanded state presence: The company's commercial presence grew from 11 states in the third quarter of 2025 to 21 states in the third quarter of 2026.
- Operating loss widened: Operating loss for the nine months ended September 30, 2026 was $12.9 million, compared to $10.8 million in the corresponding period of 2025.
- Cash position: As of September 30, 2026, cash and cash equivalents totaled approximately $8.2 million, and shareholders' equity was approximately $8.7 million.
- China regulatory approval: The company received regulatory approval from China's National Medical Products Administration to market ProSense as a Class III medical device.
- ChoICE Study progress: The first ProSense cryoablation treatment in the ChoICE Study was completed at West Cancer Center in Germantown, Tennessee, by Dr. Richard E. Fine, MD, FACS.
IceCure Medical Nine-Month 2026 Financial and Clinical Results
IceCure Medical Ltd. (NASDAQ:ICCM), headquartered in Caesarea, Israel, reported its financial and operating results for the nine months ended September 30, 2026. According to the filing, total revenues increased approximately 26% to $2.6 million from $2.1 million in the same period of 2025. Gross profit rose approximately 22% to $762,000, compared to $626,000 in the prior-year period.
The filing disclosed that research and development expenses increased to $6.5 million from $5.1 million, "primarily reflecting increased expenses related to the ChoICE Study and other clinical and development activities." Sales and marketing expenses were $3.6 million, up from $3.0 million, with the company attributing the increase to continued expansion of U.S. commercial activities. General and administrative expenses were $3.5 million, compared to $3.3 million in the corresponding period of 2025. The net loss for the nine-month period was $12.9 million, compared to $10.8 million a year earlier.
On the operational side, the filing noted that subsequent to the end of the third quarter, three additional clinical sites joined the ChoICE Study, including Legacy Health in Portland, Oregon. The company also reported the enrollment of the first two patients in the ChoICE Study at West Cancer Center in Tennessee and Adventist Health Glendale in California. Internationally, the company reported signing an exclusive distribution agreement for ProSense cryoablation systems in the Netherlands. The filing also noted that the Society of Interventional Oncology submitted a formal petition to the National Comprehensive Cancer Network to include percutaneous cryoablation as a treatment option in its breast cancer guidelines. The filing contains forward-looking statements that are the company's own and subject to its cautionary language.
What Was Disclosed
IceCure Medical disclosed nine-month 2026 financial results including a 26% revenue increase to $2.6 million, a net loss of $12.9 million, cash of approximately $8.2 million, and operational updates covering U.S. commercial expansion, the ChoICE Study, and international regulatory progress.




Please wait processing your request...